Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (TriMix-Ipi)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Vrije Universiteit Brussel
Information provided by (Responsible Party):
Bart Neyns, Universitair Ziekenhuis Brussel
ClinicalTrials.gov Identifier:
NCT01302496
First received: February 23, 2011
Last updated: October 25, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)